Skip to main content

Table 2 Patient characteristics

From: Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer

  n = 196 (%); median range
Sex
 female 73 (37.1)  
 male 123 (62.9)  
Medically inoperable 182 (92.8)  
Medically operable 14 (7.2)  
Localization
 -central 83 (42.3)  
 -peripheral 113 (57.7)  
Side
 -left 86 (43.9)  
 -right 110 (56.1)  
Grading (G)
 G1 7 (3.6)  
 G2 74 (37.8)  
 G3 42 (21.4)  
Stage according to UICC (7th edition)  
 -I 113 (57.7)  
 -II 68 (34.6)  
 -IIIa 15 (7.7)  
Histology
 -Adenocarcinoma 49 (39.9)  
 -Squamous cell carcinoma 71 (57.7)  
 -Large cell carcinoma 3 (2.4)  
 -No biopsy due to comorbidities 73 (37.2)  
Age 67 29–86
 0–50 6 (3.1)  
 50–65 63 (32.1)  
 66–80 101 (51.5)  
 > 80 26 (13.3)  
aCCI 7 3–16
 0–3 4 (2.0)  
 4–6 63 (32.1)  
 7–9 62 (31.6)  
 10–12 44 (22.4)  
 > 12 23 (11.9)  
Hypertension 119 (60.7)  
Diabetes with or without end-organ damage 52 (26.6)  
Moderate/severe renal damage 63 (32.1)  
COPD 167 (85.2)  
 -Gold 1 + 2 51 (26.0)  
 -Gold 3 61 (31.1)  
 -Gold 4 55 (28.1)  
Peripheral vascular disease 49 (25)  
Myocardial infarction 31 (15.8)  
Congestive heart failure 71 (36.2)  
Cerebral vascular disease 13 (6.6)  
Mild liver disease 9 (4.5)  
Isocenter Dose
 -peripheral tumor 18.75 18–20
 -central tumor 7.5 7–9
Packyears 40 0–120